
AstraZeneca has revealed new results from a Phase III trial investigating the efficacy of its Lynparza drug as a monotherapy …

Mylan’s recent EpiPen price inflation scandal has reignited a seemingly never-ending debate on the power of drug companies to charge …

The latest issue of Pharmafocus is now live and ready to be read! We’ve taken the opportunity to cover some of …

Nordic Nanovector has announced that they have formed a partnership with WILEX subsidiary, Heidelberg Pharma. Heidelberg Pharma specialises in the …

The Competition and Marketing Authority has launched an investigation into a number of drug companies following claims that 32 drugs …

The backlash against the over-prescription of ‘testosterone boosters’ continues in the US, with the FDA taking action to add clear …

New research from the University of Huddersfield has shed light on a new lab technique which could aid in the …

MSD, known as Merck in the US, has scored a big success in treating non-small cell lung cancer (NSCLC), with …

Novartis has beaten its third-quarter sales projections, announcing that new product growth and cost cuts managed to carry the company …

Indian pharmaceutical firm Dr Reddy’s Laboratories has suffered a drop of 60.12% in consolidated net profit for the September quarter. …

The European Medicine Agency has begun to release to the public data on clinical trial via their own website. The …

Concordia International Corp., the Ontario-based company, has announced that its founder, Chairman and Chief Executive Officer, Mark Thompson, will leave …

According to new findings from GlobalData, the Colombian pharmaceutical market is due to grow from $5 billion in 2015 to …

The FDA has accepted a supplemental Biologics License Application (sBLA) for Bristol-Myers Squibb’s Opdivo for treatment of locally advanced unresectable …

MSD, known as Merck in the US, ended their Phase III trial of Keytruda for treatment of advanced urothelial cancer …
Biopharma company Alkermes has announced the success of its ALKS 5461 treatment in a Phase III study for the treatment …

GlaxoSmithKlien, the UK’s biggest drugmaker, is seeking approval from the FDA for a shingles (herpes zoster) vaccine. The vaccine would …

This week has seen a few big collaboration and partnerships occur, whilst there have been some major movements within immunotherapy …
Debiopharm International, the Swiss-based global biopharmaceutical group of five companies, announced that it would be entering into an agreement with …

Gilead Sciences has announced positive results from three Phase II studies upon their drug GS-4997, otherwise known as selonsertib. The …